



Compliance Declaration

California Pharmaceutical Compliance Law, SB 1765

Novartis Vaccines and Diagnostics, Inc. has developed an Integrity and Compliance Program in accordance with the “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the Office of Inspector General, U.S. Department of Health and Human Services and the California Health and Safety Code, Part 15, Division 104, § 119400-119402 (“OIG Guidance”).

To the best of our knowledge, and based upon our good faith understanding of the statutory requirements of SB 1765, we are in compliance with the basic established elements of the OIG Compliance Guidance and with our Comprehensive Integrity and Compliance Program description as published on our public websites at <http://www.novartisvaccines.com/about/compliance.shtml> and <http://www.chiron.com/public/about/compliance.jsp>.

Recognizing that compliance is a dynamic concept that must be adapted to the specific characteristics of a particular company, we are constantly reassessing the program to improve it, and will continue to do so in the coming year.

On April 20, 2006, Chiron Corporation was acquired by merger and became an indirect wholly owned subsidiary of Novartis AG, a Swiss corporation, and is now known as Novartis Vaccines and Diagnostics, Inc.

Revised June 10, 2009